Geron Corporation: Lackluster Share Price Performance Despite Reasonable Drug Launch

Group 1 - Geron Corporation (NASDAQ: GERN) has received US marketing approval for Rytelo (imetelstat) aimed at treating lower-risk myelodysplastic syndromes (LR-MDS) in mid-2024 [1] - The company has been actively marketing Rytelo for several quarters following the approval [1] - An analyst rated GERN as a hold in April 2024, indicating a cautious outlook on the stock following the approval [1]